Statement Of Cash Flows [Abstract]

Xspray Pharma - Filing #690674

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	– SEK	– SEK	131 670 SEK	131 670 SEK	– SEK	—	– SEK	– SEK	– SEK	96 698 SEK	96 698 SEK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for depreciation and amortisation expense	—	—	—	9 533 SEK	—	—	—	—	—	—	8 870 SEK	—	—
Adjustments for losses (gains) on disposal of non-current assets	—	—	—	– SEK	—	—	—	—	—	—	98,000 SEK	—	—
Interest paid, classified as operating activities	—	—	—	147,000 SEK	—	—	—	—	—	—	4,000 SEK	—	—
Interest received, classified as operating activities	—	—	—	1 611 SEK	—	—	—	—	—	—	1 878 SEK	—	—
Cash flows from (used in) operating activities	—	—	—	110 179 SEK	—	—	—	—	—	—	51 607 SEK	—	—
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities	—	—	—	24 466 SEK	—	—	—	—	—	—	1 313 SEK	—	—
Cash flows from (used in) investing activities	—	—	—	135 345 SEK	—	—	—	—	—	—	105 818 SEK	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	—	—	100 000 SEK	—	—	—	—	—	—	99 877 SEK	—	—
Payments of lease liabilities, classified as financing activities	—	—	—	2 128 SEK	—	—	—	—	—	—	2 154 SEK	—	—
Cash flows from (used in) financing activities	—	—	—	93 809 SEK	—	—	—	—	—	—	103 708 SEK	—	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	—	—	151 715 SEK	—	—	—	—	—	—	53 717 SEK	—	—
Cash and cash equivalents	120 166 SEK	—	—	—	—	—	271 881 SEK	—	—	—	—	—	325 598 SEK